EDIT: Editas Medicine, Inc. PEG Multiple

Corporate company logo of Editas Corp (EDIT)

Unique CRISPR technologies and an extensive patent portfolio ensure sustained investor interest in Editas Medicine, Inc. (EDIT). The specifics of gene editing remain independent of market cycles, relying solely on scientific breakthroughs. The PEG investment attractiveness indicator allows for tracking valuation dynamics, where the value of 0.00 reflects the metric's balance. Currently, the company is deploying capital toward research without having sources of stable cash flow.

Editas Medicine Inc (EDIT): Price/Earnings to Growth Multiple from 07/04/2022 to 11/17/2026

Analytical breakdowns for Editas Corp (EDIT)

- stock quotes and analyst forecast:
General company analysis:Editas (EDIT)
Original product of Editas

The PEG ratio relates the current P/E ratio to the earnings per share growth rate, allowing for the determination of an asset's fair value based on its dynamics. By analyzing the P/E relative to EPS growth, an investor identifies business undervaluation, which is critical for Editas Medicine, Inc. (EDIT) while maintaining strict biosafety standards in CRISPR laboratories and minimizing environmental risks during waste disposal.

Competing companies

PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x TXG|Company Value to Earnings Growth Ratio NTLA (Intellia)|Stoke Corp - PEG Multiple|BLFS: Price/Earnings to Growth Ratio|WVE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Maze Tx (MAZE)|Price/Earnings to Growth Ratio Sionna Therapeutics|Growth-Adjusted P/E Ratio PRME (Prime Medicine Corp)|PEG Multiple TSHA|PEG Multiple uniqure.com (QURE)|Price/Earnings to Growth Ratio MeiraGTx PLC MGTX|Growth-Adjusted Payback Ratio RGNX|solidbio.com - PEG Multiple|OCGN (Ocugen Pharma) - Growth-Adjusted P/E Ratio|PACB: PEG Multiple|Benitec Biopharma (BNTC) - PEG Multiple|DSGN (Design Therapeutics Inc) - PEG Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Growth-Adjusted Market Cap to Net Income|FDMT - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio LXEO (Lexeo)|Price/Earnings to Growth Ratio korrobio.com KRRO|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income